{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T07:27:58Z","timestamp":1793863678104,"version":"4.6.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Tempus Labs"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40291-023-00650-5","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T04:02:32Z","timestamp":1682481752000},"page":"499-511","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin"],"prefix":"10.1007","volume":"27","author":[{"given":"Jackson","family":"Michuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Breschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshuah","family":"Kapilivsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Manghnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"McCarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Hockenberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Mineo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Igartua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel T.","family":"Dudley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Stumpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nike","family":"Beaubier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Shirazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Morency","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Guinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6095-8788","authenticated-orcid":false,"given":"Kyle A.","family":"Beauchamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Taxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"650_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen Y-J, Ciombor KK, et\u00a0al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:329\u201359.","journal-title":"J Natl Compr Canc Netw"},{"key":"650_CR2","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMra1303917","volume":"371","author":"GR Varadhachary","year":"2014","unstructured":"Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014;371:757\u201365.","journal-title":"N Engl J Med"},{"issue":"Suppl 5","key":"650_CR3","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","volume":"26","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G, et\u00a0al. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v133\u20138.","journal-title":"Ann Oncol"},{"key":"650_CR4","unstructured":"National Comprehensive Cancer Network. Occult Primary, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw."},{"key":"650_CR5","unstructured":"Key statistics for cancers of unknown primary [Internet]. [cited 2021 Apr 13]. Available from: https:\/\/www.cancer.org\/cancer\/cancer-unknown-primary\/about\/key-statistics.html"},{"key":"650_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s10552-014-0378-2","volume":"25","author":"E Mnatsakanyan","year":"2014","unstructured":"Mnatsakanyan E, Tung W-C, Caine B, Smith-Gagen J. Cancer of unknown primary: time trends in incidence. United States Cancer Causes Control. 2014;25:747\u201357.","journal-title":"United States. Cancer Causes Control."},{"key":"650_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrclinonc.2011.158","volume":"8","author":"C Massard","year":"2011","unstructured":"Massard C, Loriot Y, Fizazi K. Carcinomas of an unknown primary origin\u2013diagnosis and treatment. Nat Rev Clin Oncol. 2011;8:701\u201310.","journal-title":"Nat Rev Clin Oncol"},{"key":"650_CR8","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1001\/jamaoncol.2020.4643","volume":"6","author":"H Hayashi","year":"2020","unstructured":"Hayashi H, Takiguchi Y, Minami H, Akiyoshi K, Segawa Y, Ueda H, et\u00a0al. Site-specific and targeted therapy based on molecular profiling by next-generation sequencing for cancer of unknown primary site: a nonrandomized phase 2 clinical trial. JAMA Oncol. 2020;6:1931\u20138.","journal-title":"JAMA Oncol"},{"key":"650_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1126\/science.286.5439.531","volume":"286","author":"TR Golub","year":"1999","unstructured":"Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et\u00a0al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531\u20137.","journal-title":"Science"},{"key":"650_CR10","doi-asserted-by":"publisher","first-page":"15149","DOI":"10.1073\/pnas.211566398","volume":"98","author":"S Ramaswamy","year":"2001","unstructured":"Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, et\u00a0al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A. 2001;98:15149\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"650_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41571-020-0359-1","volume":"17","author":"E Rassy","year":"2020","unstructured":"Rassy E, Pavlidis N. Progress in refining the clinical management of cancer of unknown primary in the molecular era. Nat Rev Clin Oncol. 2020;17:541\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"650_CR12","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1158\/1078-0432.CCR-10-2599","volume":"17","author":"GR Varadhachary","year":"2011","unstructured":"Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R, et\u00a0al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011;17:4063\u201370.","journal-title":"Clin Cancer Res"},{"key":"650_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/path.2915","volume":"225","author":"M Ferracin","year":"2011","unstructured":"Ferracin M, Pedriali M, Veronese A, Zagatti B, Gaf\u00e0 R, Magri E, et\u00a0al. MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin. J Pathol. 2011;225:43\u201353.","journal-title":"J Pathol"},{"key":"650_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jmoldx.2010.11.001","volume":"13","author":"R Pillai","year":"2011","unstructured":"Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, Buturovic L, et\u00a0al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn. 2011;13:48\u201356.","journal-title":"J Mol Diagn"},{"key":"650_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2597","volume":"2","author":"JK Grewal","year":"2019","unstructured":"Grewal JK, Tessier-Cloutier B, Jones M, Gakkhar S, Ma Y, Moore R, et\u00a0al. Application of a neural network whole transcriptome-based pan-cancer method for diagnosis of primary and metastatic cancers. JAMA Netw Open. 2019;2: e192597.","journal-title":"JAMA Netw Open"},{"key":"650_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103030","volume":"61","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Pan Z, Namburi S, Pattison A, Posner A, Balachander S, et\u00a0al. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. EBioMedicine. 2020;61: 103030.","journal-title":"EBioMedicine"},{"key":"650_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3985","author":"A Penson","year":"2019","unstructured":"Penson A, Camacho N, Zheng Y, Varghese AM, Al-Ahmadie H, Razavi P, et\u00a0al. Development of genome-derived tumor type prediction to inform clinical cancer care. JAMA Oncol. 2019. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3985.","journal-title":"JAMA Oncol"},{"key":"650_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41467-019-13825-8","volume":"11","author":"W Jiao","year":"2020","unstructured":"Jiao W, Atwal G, Polak P, Karlic R, Cuppen E, et\u00a0al. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun. 2020;11:728.","journal-title":"Nat Commun"},{"key":"650_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MC Liu","year":"2020","unstructured":"Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV. CCGA Consortium Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745\u201359.","journal-title":"Ann Oncol"},{"key":"650_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41586-021-03512-4","volume":"594","author":"MY Lu","year":"2021","unstructured":"Lu MY, Chen TY, Williamson DFK, Zhao M, Shady M, Lipkova J, et\u00a0al. AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021;594:106\u201310.","journal-title":"Nature"},{"key":"650_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.5858\/2006-130-465-MCOHCU","volume":"130","author":"X-J Ma","year":"2006","unstructured":"Ma X-J, Patel R, Wang X, Salunga R, Murage J, Desai R, et\u00a0al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006;130:465\u201373.","journal-title":"Arch Pathol Lab Med"},{"key":"650_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jmoldx.2011.04.004","volume":"13","author":"MG Erlander","year":"2011","unstructured":"Erlander MG, Ma X-J, Kesty NC, Bao L, Salunga R, Schnabel CA. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn. 2011;13:493\u2013503.","journal-title":"J Mol Diagn"},{"key":"650_CR23","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1158\/1078-0432.CCR-12-0920","volume":"18","author":"SE Kerr","year":"2012","unstructured":"Kerr SE, Schnabel CA, Sullivan PS, Zhang Y, Singh V, Carey B, et\u00a0al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res. 2012;18:3952\u201360.","journal-title":"Clin Cancer Res"},{"key":"650_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","volume":"31","author":"JD Hainsworth","year":"2013","unstructured":"Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et\u00a0al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31:217\u201323.","journal-title":"J Clin Oncol"},{"key":"650_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101016","volume":"14","author":"J Abraham","year":"2021","unstructured":"Abraham J, Heimberger AB, Marshall J, Heath E, Drabick J, Helmstetter A, et\u00a0al. Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type. Transl Oncol. 2021;14: 101016.","journal-title":"Transl Oncol"},{"key":"650_CR26","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1097\/PAS.0b013e31828309c4","volume":"37","author":"CR Handorf","year":"2013","unstructured":"Handorf CR, Kulkarni A, Grenert JP, Weiss LM, Rogers WM, Kim OS, et\u00a0al. A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors. Am J Surg Pathol. 2013;37:1067\u201375.","journal-title":"Am J Surg Pathol"},{"key":"650_CR27","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.jmoldx.2021.07.009","volume":"23","author":"J Vibert","year":"2021","unstructured":"Vibert J, Pierron G, Benoist C, Gruel N, Guillemot D, Vincent-Salomon A, et\u00a0al. Identification of tissue of origin and guided therapeutic applications in cancers of unknown primary using deep learning and RNA sequencing (TransCUPtomics). J Mol Diagn. 2021;23:1380\u201392.","journal-title":"J Mol Diagn"},{"key":"650_CR28","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.18632\/oncotarget.26797","volume":"10","author":"N Beaubier","year":"2019","unstructured":"Beaubier N, Tell R, Lau D, Parsons JR, Bush S, Perera J, et\u00a0al. Clinical validation of the Tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019;10:2384\u201396.","journal-title":"Oncotarget"},{"key":"650_CR29","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41587-019-0259-z","volume":"37","author":"N Beaubier","year":"2019","unstructured":"Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, et\u00a0al. Integrated genomic profiling expands clinical options for patients with cancer. Nat Biotechnol. 2019;37:1351\u201360.","journal-title":"Nat Biotechnol"},{"key":"650_CR30","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1101\/gr.189621.115","volume":"25","author":"M Cieslik","year":"2015","unstructured":"Cieslik M, Chugh R, Wu Y-M, Wu M, Brennan C, Lonigro R, et\u00a0al. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Res. 2015;25:1372\u201381.","journal-title":"Genome Res"},{"key":"650_CR31","unstructured":"xGen Exome Research Panel [Internet]. Integrated DNA Technologies; 2020. Available from: https:\/\/www.idtdna.com\/pages\/products\/next-generation-sequencing\/targeted-sequencing\/hybridization-capture\/predesigned-panels\/xgen-exome-research-panel-v2"},{"key":"650_CR32","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.","journal-title":"Genome Biol"},{"key":"650_CR33","doi-asserted-by":"crossref","unstructured":"Hu J, Parsons J, Mineo B, Bell JSK, Malinauskas J, Drews J, et\u00a0al. Abstract 2239: Comprehensive validation of RNA sequencing for clinical NGS fusion genes and RNA expression reporting. Cancer Res. American Association for Cancer Research; 2021;81:2239\u20132239.","DOI":"10.1158\/1538-7445.AM2021-2239"},{"key":"650_CR34","doi-asserted-by":"crossref","unstructured":"SEQC\/MAQC-III Consortium. A comprehensive assessment of RNA-seq accuracy, reproducibility and information content by the Sequencing Quality Control Consortium. Nat Biotechnol. 2014;32:903\u201314.","DOI":"10.1038\/nbt.2957"},{"key":"650_CR35","unstructured":"The Cancer Genome Atlas program [Internet]. National Cancer Institute. 2018 [cited 2022 Mar 18]. Available from: https:\/\/www.cancer.gov\/tcga"},{"key":"650_CR36","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"CGA Network","year":"2012","unstructured":"Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330\u20137.","journal-title":"Nature"},{"key":"650_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03512-4","author":"MY Lu","year":"2021","unstructured":"Lu MY, Chen TY, Williamson DFK, Zhao M, Shady M, Lipkova J, et\u00a0al. AI-based pathology predicts origins for cancers of unknown primary. Nature. 2021. https:\/\/doi.org\/10.1038\/s41586-021-03512-4.","journal-title":"Nature"},{"key":"650_CR38","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1126\/science.aaw3472","volume":"363","author":"KM Haigis","year":"2019","unstructured":"Haigis KM, Cichowski K, Elledge SJ. Tissue-specificity in cancer: the rule, not the exception. Science. 2019;363:1150\u20131.","journal-title":"Science"},{"key":"650_CR39","unstructured":"NCCN Guidelines Non-Small Cell Lung Cancer [Internet]. National Comprehensive Cancer Network; 2020 Dec. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"650_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/JTO.0b013e3181fc0878","volume":"6","author":"DC Paech","year":"2011","unstructured":"Paech DC, Weston AR, Pavlakis N, Gill A, Rajan N, Barraclough H, et\u00a0al. A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6:55\u201363.","journal-title":"J Thorac Oncol"},{"key":"650_CR41","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cllc.2012.01.004","volume":"13","author":"AL Moreira","year":"2012","unstructured":"Moreira AL, Thornton RH. Personalized medicine for non-small-cell lung cancer: implications of recent advances in tissue acquisition for molecular and histologic testing. Clin Lung Cancer. 2012;13:334\u20139.","journal-title":"Clin Lung Cancer"},{"key":"650_CR42","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","volume":"14","author":"Y Yatabe","year":"2019","unstructured":"Yatabe Y, Dacic S, Borczuk AC, Warth A, Russell PA, Lantuejoul S, et\u00a0al. Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J Thorac Oncol. 2019;14:377\u2013407.","journal-title":"J Thorac Oncol"},{"key":"650_CR43","unstructured":"Center for Drug Evaluation, Research. FDA grants accelerated approval to pemigatinib for cholangiocarcinoma [Internet]. 2020 [cited 2021 Sep 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pemigatinib-cholangiocarcinoma-fgfr2-rearrangement-or-fusion"},{"key":"650_CR44","unstructured":"Center for Drug Evaluation, Research. FDA approves ivosidenib for advanced or metastatic cholangiocarcinoma [Internet]. 2021 [cited 2021 Sep 3]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-advanced-or-metastatic-cholangiocarcinoma"},{"key":"650_CR45","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00428-017-2148-5","volume":"471","author":"A Agaimy","year":"2017","unstructured":"Agaimy A, Fuchs F, Moskalev EA, Sirbu H, Hartmann A, Haller F. SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1neg\/CK7pos\/HepPar-1pos immunophenotype. Virchows Arch. 2017;471:599\u2013609.","journal-title":"Virchows Arch"},{"key":"650_CR46","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5858\/arpa.2019-0633-OA","volume":"145","author":"A Nambirajan","year":"2021","unstructured":"Nambirajan A, Singh V, Bhardwaj N, Mittal S, Kumar S, Jain D. SMARCA4\/BRG1-deficient non-small cell lung carcinomas: a case series and review of the literature. Arch Pathol Lab Med. 2021;145:90\u20138.","journal-title":"Arch Pathol Lab Med"},{"key":"650_CR47","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et\u00a0al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231\u201351.","journal-title":"Neuro Oncol"},{"key":"650_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101405","author":"GK Patel","year":"2019","unstructured":"Patel GK, Chugh N, Tripathi M. Neuroendocrine differentiation of prostate cancer-an intriguing example of tumor evolution at play. Cancers. 2019. https:\/\/doi.org\/10.3390\/cancers11101405.","journal-title":"Cancers"},{"key":"650_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1200\/JCO.18.01585","volume":"37","author":"N Marcoux","year":"2019","unstructured":"Marcoux N, Gettinger SN, O\u2019Kane G, Arbour KC, Neal JW, Husain H, et\u00a0al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol. 2019;37:278\u201385.","journal-title":"J Clin Oncol"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00650-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-023-00650-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-023-00650-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T13:22:14Z","timestamp":1687872134000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-023-00650-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["650"],"URL":"https:\/\/doi.org\/10.1007\/s40291-023-00650-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.06.22274683","asserted-by":"object"}]},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"2 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Funding for this project and open access\u00a0was provided directly by Tempus Labs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees, former employees, and\/or hold restricted stock units of Tempus Labs, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Raw data for this study were generated at Tempus Labs. Derived data supporting the findings of this study are available within the paper and its Supplementary Figs.\/Tables. Requests for additional data should be addressed to <u>publication.inquiry@tempus.com<\/u>. Due to the clinical nature of these samples, requests will be evaluated by a Data Access Review Group and are subject to a signed data transfer agreement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Analyses were performed using de-identified data under the exemption Pro00042950, granted from the Advarra, Inc Institutional Review Board (IRB) on 15 April 2020 based on the Department of Health and Human Services regulations found at \u201c45 CFR 46.104(d)(4).\u201d All methods were carried out in accordance with relevant guidelines and regulations. Internal validations and laboratory protocols were developed and performed in a CLIA-certified, CAP-accredited laboratory.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent is not required from the subject\/s or legal guardians per the above-stated exemption (consent was exempted by Advarra Inc. Institutional Review Board).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N\/A.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"JM, AB, JK, AJH, JG, KAB, and TT conceptualized the work. BM performed wet-lab experiments. JM, KM, NB, MS, RJ, EM, KAB, and TT curated data. MB, AB, JK, KM, CM, and KAB wrote the software. JM and JK provided the formal analysis and validation. MCS, NB, MS, RJ, EM, KB, JG, KAB, and TT supervised the work. JM, KM, AJH, JG, KAB, and TT contributed to data visualization. All authors participated in drafting the manuscript. JM, JK, KM, AJH, CI, JTD, MCS, NB, JG, KAB, and TT edited the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}